Business Overview: Outset Medical, Inc. (NASDAQ: OM)

---

Executive Summary

Outset Medical, Inc. is a medical technology company that designs, manufactures, and markets the Tablo Hemodialysis System, a single, FDA-cleared console intended to simplify hemodialysis across every care setting — hospitals, outpatient clinics, and patients' own homes. Founded in 2003 and headquartered in San Jose, California, Outset built Tablo as a ground-up reinvention of dialysis technology: a compact, touchscreen-driven device that purifies tap water and manufactures dialysate on demand, eliminating the dedicated water-treatment rooms, specialized plumbing, and highly trained technicians that legacy dialysis machines require.

Outset matters because it is one of very few companies attempting to meaningfully disrupt a dialysis equipment market long dominated by vertically integrated giants (Fresenius Medical Care and DaVita). By selling a single enterprise platform that follows the patient from the acute hospital bed to a skilled nursing facility to their living room, Outset is betting that ease-of-use and site-of-care flexibility — not incumbents' decades of installed infrastructure — will define the next generation of kidney care. As of fiscal year 2025, the company serves more than 1,000 U.S. healthcare facilities and continues to scale toward sustained profitability after several years of heavy losses tied to its commercial launch.

---

1. Core Business Model & How They Work

Outset operates a classic "razor-and-blade" medical device model: it places or sells the durable Tablo console, then earns higher-margin, recurring revenue from the single-use cartridges and services consumed with every treatment.

[ Console Sale / Placement ] ➡️ [ Facility or Home Onboarding & Training ] ➡️ [ Recurring Cartridge & Consumable Sales ] ➡️ [ Service & Software (TabloHub / MyTablo) ] ➡️ [ Expanded Site-of-Care Use ]

Key Operational Drivers

1. Console Placements Drive the Installed Base: Outset sells or places Tablo consoles with acute-care hospitals, post-acute facilities (skilled nursing, long-term acute care), and individual home patients. Each placement is a long-duration revenue commitment, since dialysis — unlike most medical procedures — is a recurring, often lifelong, treatment.
2. Recurring Revenue from Consumables: Every treatment requires a single-use Tablo Cartridge, creating a predictable, repeat-purchase revenue stream that grew to roughly $88.7 million in FY2025, about three-quarters of total revenue.
3. One Platform, Three Care Settings: Unlike legacy dialysis equipment, which requires different machines (and often different staff skill sets) for acute, in-center, and home use, Tablo is designed to work — and be reimbursed — across all three, which Outset argues lowers the system-wide cost of training, logistics, and capital equipment for its customers.
4. Margin Expansion Through Scale and Cost-Down: Management has prioritized gross margin improvement (GAAP gross margin rose from 33.9% in FY2024 to 39.1% in FY2025) via manufacturing cost reductions and operating-expense discipline, as the company works toward sustained profitability.

---

2. Business Segments

Outset Medical does not report distinct financial reporting segments; it operates as a single operating segment built around the Tablo platform, sold into three overlapping markets (acute care, post-acute/skilled nursing, and home dialysis). This section is omitted per the single-segment guidance, and the three markets are instead treated as go-to-market channels in the Product Portfolio and Competitive Landscape sections below.

---

3. Product Portfolio

---

4. Competitive Landscape

Outset competes against both vertically integrated dialysis-services giants and smaller device-focused challengers. Positioning varies meaningfully by care setting.

                 HOME / PORTABLE CAPABILITY
                 Low                              High
            ┌───────────────────────────────────────────┐
     High   │                              [Outset/Tablo]│
   INSTALLED│                    [Fresenius/NxStage]     │
    BASE &  │         [Mozarc (DaVita/Medtronic JV)]     │
   VERTICAL │   [Vantive (ex-Baxter)]                    │
INTEGRATION │ [B. Braun]                                 │
     Low    │ [Quanta Dialysis]                          │
            └───────────────────────────────────────────┘

Competitors by Care Setting

Acute & Post-Acute Hospital Dialysis

• Key Competitors: Fresenius Medical Care, B. Braun Medical, Vantive (formerly Baxter's kidney care business).
• Dynamics: Fresenius is the largest and most vertically integrated player in dialysis globally, owning everything from machines to clinics to care-delivery networks. Outset competes here on Tablo's simplicity — a single nurse-operable console versus machines that often require dedicated water-treatment infrastructure and specialized technicians.

Home Hemodialysis

• Key Competitors: Fresenius (via its NxStage home hemodialysis system), Mozarc Medical (a DaVita/Medtronic joint venture entering the space), Quanta Dialysis Technologies.
• Dynamics: This is Outset's most strategically important and most contested battleground. NxStage has a long incumbency in home hemodialysis, but Outset argues Tablo's simpler setup and smaller footprint make it easier for patients to train on and use independently. Mozarc's entry (backed by two of the industry's largest players) is a notable emerging threat to watch.

In-Center / Outpatient Dialysis

• Key Competitors: DaVita and Fresenius-owned dialysis clinics (the dominant U.S. in-center dialysis providers, together running the large majority of U.S. dialysis clinics).
• Dynamics: Outset has limited penetration here today; its core wedge is acute and home care rather than displacing entrenched in-center infrastructure.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Single-Platform Design Across Care Settings: Tablo's ability to serve acute, post-acute, and home settings with one FDA-cleared device is a genuine engineering differentiator that legacy multi-machine incumbents cannot easily replicate without a full redesign.
• Simplified Water Purification: Eliminating the need for a dedicated water-treatment room is Tablo's single most defensible technical advantage, directly lowering facilities' capital and staffing costs.
• Growing, Sticky Installed Base: Over 1,000 U.S. healthcare facilities now use Tablo, and because dialysis is a recurring, often lifelong treatment, each placement anchors years of consumable revenue.
• Improving Unit Economics: GAAP gross margin expanded from 33.9% (FY2024) to 39.1% (FY2025), with FY2026 guidance in the low-to-mid 40% non-GAAP range, evidence that the commercial model can scale toward profitability.

Strategic Risks & Vulnerabilities

1. Scale Disadvantage Against Vertically Integrated Giants: Fresenius and DaVita together control the vast majority of U.S. dialysis clinics and have far greater capital, manufacturing scale, and payer relationships. Outset's cost base is not yet competitive with these incumbents on a pure cost-per-treatment basis.
2. History of Significant Losses: Outset has posted substantial net losses every year since its 2020 IPO — $172.8 million (2023), $128.0 million (2024), and $81.7 million (2025) — alongside an accumulated deficit of roughly $1.2 billion. While losses are narrowing quickly, the company is not yet profitable, and continued execution on cost reduction is required to reach that point.
3. Intensifying Home Dialysis Competition: Mozarc Medical, a joint venture backed by DaVita and Medtronic — two of the deepest-pocketed players in kidney care — is a direct new entrant into home hemodialysis, Outset's key growth vector.
4. Revenue Growth Has Decelerated: Full-year 2025 revenue grew only 5% (to $119.5 million), and Q4 2025 revenue actually declined 2% year over year, a reminder that console placement cycles can be uneven and that the growth story has not yet reaccelerated meaningfully.
5. Capital Structure and Covenant Sensitivity: The company has flagged risk factors tied to its credit agreement, including interest-rate exposure and the need to remain in compliance with financial covenants — a real, if currently manageable, constraint given the company's history of cash consumption.
6. Regulatory and Reimbursement Dependence: As an FDA-regulated device sold into a heavily Medicare-reimbursed therapy category, any adverse regulatory action, reimbursement change, or delay to its next-generation Tablo launch (expected Q2 2026) would directly affect the growth trajectory.

---

6. Financial Overview

---

7. Summary Conclusion

Outset Medical's investment case rests on a straightforward but difficult-to-execute idea: that a single, simplified hemodialysis platform can out-compete decades-old, vertically integrated incumbents by removing the friction — specialized plumbing, dedicated technicians, setting-specific machines — that has long made dialysis expensive and inflexible. The Tablo Hemodialysis System's ability to move with the patient from hospital to post-acute facility to home gives Outset a genuine, hard-to-copy product differentiator, and FY2025's results (narrowing losses, expanding gross margin, and sharply reduced cash burn) show real progress toward a sustainable financial model.

The company's biggest forward risk is less about solvency — it ended 2025 with $172.8 million in liquidity, no going-concern disclosure, and management describing itself as "well capitalized" — and more about competitive intensity and growth reacceleration: Fresenius's NxStage and the new Mozarc Medical joint venture (DaVita/Medtronic) are both pressing into home hemodialysis just as Outset needs that channel to drive the next leg of growth. The upcoming next-generation Tablo launch in Q2 2026 is the near-term catalyst that will determine whether Outset can convert its technical differentiation into reaccelerated, durable revenue growth before larger rivals close the gap.